A single nucleotide polymorphism (SNP) at codon 388 of FGFR4 (Gly388Arg), which encodes an amino acid in the transmembrane domain of the FGFR4 gene, was reported to be associated with poor outcome in sarcoma [11], prostate [12], lung [13, 14], colon [15], and head and neck carcinomas [16], melanoma [17], and advanced breast cancer [18]. This evidence concerns the gene FGFR4 and breast carcinoma.